These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 7617408)

  • 1. Pulmonary hypertension in respiratory distress syndrome.
    Golan A; Zalzstein E; Zmora E; Shinwell ES
    Pediatr Pulmonol; 1995 Apr; 19(4):221-5. PubMed ID: 7617408
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of tolazoline for treatment of severe hypoxemia in extremely preterm infants.
    Nuntnarumit P; Korones SB; Yang W; Bada HS
    Pediatrics; 2002 May; 109(5):852-6. PubMed ID: 11986446
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhaled iloprost in the treatment of pulmonary hypertension in very low birth weight infants: a report of two cases.
    Gokce I; Kahveci H; Turkyilmaz Z; Adakli B; Zeybek C
    J Pak Med Assoc; 2012 Apr; 62(4):388-91. PubMed ID: 22755287
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tolazoline and dopamine therapy in neonatal hypoxia and pulmonary vasospasm.
    Hegyi T; Hiatt IM
    Acta Paediatr Scand; 1980 Jan; 69(1):101-3. PubMed ID: 7368901
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of tolazoline on persistent hypoxemia in neonatal respiratory distress.
    Purohit DM; Pai S; Levkoff AH
    Crit Care Med; 1978; 6(1):14-8. PubMed ID: 639525
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A controlled trial of synthetic surfactant in infants weighing 1250 g or more with respiratory distress syndrome. The American Exosurf Neonatal Study Group I, and the Canadian Exosurf Neonatal Study Group.
    Long W; Corbet A; Cotton R; Courtney S; McGuiness G; Walter D; Watts J; Smyth J; Bard H; Chernick V
    N Engl J Med; 1991 Dec; 325(24):1696-703. PubMed ID: 1944470
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Patent ductus arteriosus hemodynamics in very premature infants treated with poractant alfa or beractant for respiratory distress syndrome.
    Fujii A; Allen R; Doros G; O'Brien S
    J Perinatol; 2010 Oct; 30(10):671-6. PubMed ID: 20336077
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Multiple versus single doses of exogenous surfactant for the prevention or treatment of neonatal respiratory distress syndrome.
    Soll R; Ozek E
    Cochrane Database Syst Rev; 2009 Jan; (1):CD000141. PubMed ID: 19160177
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of patent ductus arteriosus on left ventricular output and organ blood flows in preterm infants with respiratory distress syndrome treated with surfactant.
    Shimada S; Kasai T; Konishi M; Fujiwara T
    J Pediatr; 1994 Aug; 125(2):270-7. PubMed ID: 8040777
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Persistent pulmonary hypertension of the newborn: pathogenesis, etiology, and management.
    Ostrea EM; Villanueva-Uy ET; Natarajan G; Uy HG
    Paediatr Drugs; 2006; 8(3):179-88. PubMed ID: 16774297
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Meconium aspiration syndrome with severe hypoxemia. Treatment with a pulmonary vasodilator (tolarzoline) (author's transl)].
    Omeñaca F; Navarro C; Barrio C; Pérez Rodríguez J; García Frías E; Quero J; Moreno F
    An Esp Pediatr; 1979 Feb; 12(2):123-30. PubMed ID: 426388
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The relationship of symptomatic patent ductus arteriosus to respiratory distress in premature newborn infants.
    Cotton RB
    Clin Perinatol; 1987 Sep; 14(3):621-33. PubMed ID: 3311542
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Increased systemic vascular resistance in neonates with pulmonary hypertension.
    Milstein JM; Goetzman BW; Riemenschneider TA; Wennberg RP
    Am J Cardiol; 1979 Nov; 44(6):1159-62. PubMed ID: 495510
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Use of tcPO2 for evaluation of right to left shunts in patent ductus arteriosus.
    Peabody JL; Schachinger H; Huch R; Huch A
    J Perinat Med; 1981; 9 Suppl 1():120-2. PubMed ID: 7229860
    [No Abstract]   [Full Text] [Related]  

  • 15. Refractory hypoxemia associated with neonatal pulmonary disease: the use and limitations of tolazoline.
    Stevenson DK; Kasting DS; Darnall RA; Ariagno RL; Johnson JD; Malachowski N; Beets CL; Sunshine P
    J Pediatr; 1979 Oct; 95(4):595-9. PubMed ID: 480041
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Surfactant replacement therapy for respiratory distress syndrome: a pilot study].
    Shinwell ES; Zmora E; Leven D; Berger I; Karplus M
    Harefuah; 1992 Jul; 123(1-2):1-4, 72. PubMed ID: 1505835
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The critically ill premature infant with patent ductus arteriosus and pulmonary disease-an echocardiographic assessment.
    Baylen BG; Meyer RA; Kaplan S; Ringenburg WE; Korfhagen J
    J Pediatr; 1975 Mar; 86(3):423-32. PubMed ID: 123007
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [The persistence of foetal circulation. Neonatal pulmonary arterial hypertension. Favourable action of tolazoline (author's transl)].
    Monin P; Vert P
    Nouv Presse Med; 1978 Sep; 7(32):2853-4, 2859-61. PubMed ID: 714666
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cardiovascular effects of patent ductus arteriosus in preterm lambs with respiratory distress.
    Clyman RI; Mauray F; Heymann MA; Roman C
    J Pediatr; 1987 Oct; 111(4):579-87. PubMed ID: 3655990
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pulmonary effects of closure of patent ductus arteriosus in premature infants with severe respiratory distress syndrome.
    Farstad T; Bratlid D
    Eur J Pediatr; 1994 Dec; 153(12):903-5. PubMed ID: 7859794
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.